rhinosinusitis%20-%20acute,%20bacterial
RHINOSINUSITIS - ACUTE, BACTERIAL
Acute bacterial rhinosinusitis is the mucosal inflammation of the nose and paransal sinuses caused by bacteria lasting >10 days for up to 4 weeks or symptoms worsening for 5-7 days and is <12 weeks with complete resolution of symptoms.
It is often preceded by a viral upper respiratory tract infection.
Signs and symptoms are nonspecific and typically difficult to differentiate from viral upper respiratory tract infection.
There is fever with nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without facial pressure/pain/fullness and reduction/loss of smell.
Streptococcus pneumoniae and unencapsulated strains of Haemophilus influenzae cause half of acute rhinosinusitis cases.

Definition

  • Mucosal inflammation of the nose and paranasal sinuses caused by bacteria lasting ≥10 days for up to 4 weeks with no clinical improvement, severe signs or symptoms [eg high fever (39°C), purulent nasal discharge, facial pain] of ≥3-4 consecutive days, and worsening of symptoms within 10 days after initial improvement
  • Often preceded by a viral upper respiratory tract infection (URTI), rhinitis or other conditions that impair local or systemic immune function (eg nonallergic rhinitis, dental infection, mechanical obstruction of the nose, cystic fibrosis, ciliary dysfunction, immunodeficiency that impair the sinus drainage)
  • Incidence in women is higher than men

Etiology

  • S pneumoniae and unencapsulated strains of H influenzae cause approximately 75% of acute rhinosinusitis cases
  • M catarrhalis account for 2-10% of the cases and is more common among children
  • 3-7% of the cases may be due to S pyogenes and anaerobic bacteria
  • S aureus and other Streptococcal sp may occasionally cause rhinosinusitis
  • Rarely Gram-negative bacilli are recovered in cases of acute rhinosinusitis
  • Microaerophilic and anaerobic bacteria may be identified and isolated if the acute bacterial rhinosinusitis (ARBS) is due to the extension of dental root infection to the sinus cavity

Pathophysiology

  • Occurs as a complication of a viral infection
    • Can be associated with rhinitis or other conditions that obstruct the nose or impair immune function (local or systemic)

Signs and Symptoms

  • Signs and symptoms are nonspecific and it is typically difficult to differentiate from viral upper respiratory tract infection (URTI)
  • There is nasal obstruction/congestion or anterior and/or posterior purulent drainage, with or without
    • Facial pressure/pain/fullness
    • Reduction/loss of smell
  • Other signs and symptoms include fever, fatigue, headache, ear pressure/discomfort, throat pain, halitosis, maxillary dental pain, facial swelling or periorbital edema, cough

Risk Factors

  • Most common predisposing factor to acute bacterial rhinosinusitis (ABRS) is viral upper respiratory tract infection (URTI)
  • Other factors:
    • Presence of medical conditions (eg allergic rhinitis, cystic fibrosis, immunodeficiency, etc)
    • Irritants (eg environmental tobacco smoke, air pollution, chlorine)
    • Anatomic (eg deviated septum, adenoidal hypertrophy, immotile cilia, polyps, tumors and foreign bodies)
    • Odontogenic sources
    • Medications (eg overuse of topical decongestants, cocaine abuse)
    • Trauma (eg dental procedure, diving)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Roshini Claire Anthony, 03 Feb 2020

The emergence of a novel coronavirus (preliminarily referred to as 2019-nCoV) has taken hold of public attention in the last month. MIMS Doctor speaks to Professor Dale Fisher, a senior consultant at the Division of Infectious Diseases, National University Hospital, Singapore, to get a better picture of the situation and steps being undertaken in Singapore to prevent spread of the virus.

Pearl Toh, 04 Feb 2020
Four months of daily rifampicin is safer than 9 months of daily isoniazid when it comes to treating latent tuberculosis (TB) infection, according to a post hoc safety analysis on pooled data from two randomized studies* — thus rendering the ambitious goal by the WHO to treat 30 million patients possible.
Jairia Dela Cruz, 31 Jan 2020
A week-long course of the centrally acting neurokinin-1 inhibitor aprepitant for treating cough in advanced lung cancer patients is effective and safe, producing significant improvements in cough severity and impact without increasing severe side effects, according to the results of a trial.